Novo Nordisk (NVO) stock

Diabetes medicinesGLP-1 and obesity drugs

Worth $178B

Pre-market

$41.00

+1.71%

Diabetes medicines, worth $178BGLP-1 and obesity drugs

Close $40.31 +0.02%

As of 9:27 AM ET pre-market, delayed 15+ min · Live for Pro members

Quality Score

Below Average

In its industry

#38of 90

Pharma

Checks firing

2of 14

Transition

From 52-week high

-37.2%

under its best in a year

NVO's Quality Score was unchanged on Fri, Nov 6, at 4.

Follow NVO's trial news. Pro members can get an alert when Novo Nordisk files news, and see its trials, share raises, and its CEO's filings.

Get an alert when NVO files news on its trialsSee it live, free for 24 hours. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextJan 29, 2027 · In 81 daysZiltivekimab, Phase 3 ARTEMIS, the sponsor's estimatePhase 3 main data due · ClinicalTrials.gov · Sep 9

Why NVO lags the market

Down 57% over three years while the S&P 500 rose 75%.

Its filings show the business growing while the shares lagged the market.

No filing or news in our sources explains it.

Sources: Price history, Nov 6, 2026; Its high and its filings, Nov 6, 2026; Annual reports, Dec 31, 2025

−3Long-term trend below a falling 200-day average, down over one year, down over two years

The other side, the timeline, and its peers, for Pro members.

Key facts on NVO

Key facts on NVO
Since its 2024 high	Down 73% while sales grew 33%
Latest filing	6-K, Oct 5 Issued a release: "Novo provides update on the denecimig Biologics License Application (BLA) in the US"

1 more reason behind NVO's 4, free with an account →2 more reasons behind NVO's 4, for Pro members.

NVO in the news

Thu Nov 5Citi raises Novo Nordisk stock target despite 'mixed' results By Investing.com investing.com uk and 1 more · yesterday 6:50 AM ET NVO closed −4.5% that day.

Big story

Guidance

Novo Nordisk raises 2026 outlook as Wegovy pill beats forecasts

NVO closed +5.0% that day on 2.2x normal volume.

Reported by Reuters · covered by 27 outlets

Get an alert on NVO's next big story →

Outlet counts from the GDELT Project. The move is what NVO did that session, not a claim about why.

What's next

Tue Nov 10: Financial Times Global Pharma and…Industry event · date confirmed.

Get an alert when NVO's Quality Score turns up →

1 more date ahead: the conference, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

NVO catalysts

Coming up

After its last 4 reports it closed -1.8% on average, higher 3 of 4 times.

18 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for NVO

Next Phase 3 data on the registry

Jan 29, 2027In 81 daysZiltivekimab, Phase 3 ARTEMIS: ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart AttackPhase 3 main data due · ClinicalTrials.gov · Sep 9

What it means: the date the registry lists for the trial’s last main measurement, as the sponsor estimates it. Results usually follow weeks to months later.

Lead program: Ziltivekimab
Another trial: ONWARDS 11Phase 3 · Active · 877 people · main data estimated Jan 25, 2027 · NCT07076199

101 more trials, 4 with data due this year, 15 drugs past Phase 1, 12 drug news items, and 223 filings, for Pro members.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

For Pro members: every trade.

Get an alert when NVO files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

How NVO ranks in Pharma

NVO is #38 of 90 by Quality Score.

How NVO ranks in Pharma
Rank	Stock	Checks	Quality Score
1	ABBVAbbVie	8/14	24
2	LLYEli Lilly	5/14	18
3	CRONCronos	5/14	18
	MYGNMyriad Genetics		Open for its score
	NKTXNkarta		Open for its score
	NVSNovartis		Open for its score
	OCSOculis		Open for its score
38	NVONovo Nordisk	2/14	4

When does NVO report earnings, and what happens after?

Reports Wed Feb 3, before the open (in 86 days). Confirmed.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

Close after the report, last 3

+2.0%+0.6%+5.0%

May 6Aug 5Nov 4

Reported	When	Gap	Reaction	5 days
Nov 4, 2026Before open	Before open	+5.6%	+5.0%	not yet
Aug 5, 2026Before open	Before open	+1.2%	+0.6%	+6.5%
May 6, 2026Before open	Before open	+3.2%	+2.0%	+4.8%

NVO closed higher after 3 of its last 4 reports.

6 quarters of NVO’s results read from its 6-K filings, the newest filed Nov 4, 2026: its sales and profit, quarter by quarter, for Pro members.

All 4 reports, and NVO's Quality Score going into each

NVO sales and profit by year

Sales and profit by year

Sales grew every year from 2019 to 2025, to DKK 309B. It made a profit in each of the seven years.

NVO has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on NVO, and all 14 on every stock.Get in free →

NVO RSI on Nov 6: 52.8, below its 50-day and 200-day averages

Not scored

RSI 52.8, MACD above signal, below both averages. Not scored.13 readings

The deep dive on NVO

What it does and how it makes money4 findingsIt kept 41 cents of each dollar of sales in fiscal 2025: DKK 128B of operating profit on DKK 309B of sales.Annual report, filed Feb 4, 2026"In Japan, the drug compound patent expired in 2022; in the US and Germany, the drug compound patent expired in 2023." (20-F for fiscal 2025)SEC filing · Feb 4, 2026
Where it stands2 findingsFor Pro members2 findings on where NVO stands: its cash, debt, and share count, for Pro members
What changed in its filings1 finding"Subsequent to the ruling by the US Court of Appeals for the Third Circuit, covered entities filed Administrative Dispute Resolution ('ADR') petitions against the Company before the Health Resources and Services Administration ('HRSA') to recover alleged overcharges related to the 340B Drug Pricing Program." (20-F for fiscal 2025)SEC filing · Feb 4, 2026
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades NVO, for Pro members
Against its closest peers3 peersFor Pro membersNVO against 3 peers, fact by fact, for Pro members

7 more findings on NVO, each with its source, for Pro members.

NVO insider trades

NVO trades by Congress and the executive branch

4 trades disclosed in the last six months. The newest:

SellKevin Hern$1K to $15KHousetraded Sep 10, disclosed Sep 25(15 days later)

SellKevin HernHouse$1K to $15Ktraded Sep 10, disclosed Sep 25(15 days later)

All 4 trades on NVO disclosed by Congress and the executive branch, for Pro members.Get in free →

See what Congress is buying across the market

About Novo Nordisk

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

69,500 employeesnovonordisk.com

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on NVO and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn NVO's score around: 5 things
9 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaySep 17Scott Franklin bought NVO$1K to $15K, disclosed Sep 17

Alerts are optional.

See NVO's 14 chart checks

See it live, free for 24 hours. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: NVO's Quality Score is 4 (Below Average), #38 of 90 in Pharma.

What does NVO's Quality Score say?

NVO scores 4 today, which Breakaway calls Below Average. It is #38 of 90 in Pharma by Quality Score, with 2 of 14 chart checks firing. Down 57% over three years while the S&P 500 rose 75%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is NVO's Quality Score?

NVO scores 4 today, which Breakaway calls Below Average (0 to 5). That is #38 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NVO's 4.

When does NVO report earnings?

Reports Wed Feb 3, before the open, a date the company confirmed. NVO closed higher after 3 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.